Tempostatin™ (halofuginone) inhibits collagen deposition in fibrous capsules

K. C. Olbrich*, R. A. Meade, W. Bruno, B. M. Sundin, L. Heller, D. Erdmann, L. S. Levin, B. Klitzman

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

A study proposed to see the effectiveness of a collagen type I synthesis inhibitor, Tempostatin™ (Halofuginone), at inhibiting collagen deposition around implanted materials was discussed. The data indicated that halofuginone was effective at inhibiting the deposition of collagen within the capsule that formed around the implanted silicone. It was also indicated that halofuginone inhibited collagen synthesis by inhibiting TGF-β activity. The presence of TGF-beta in the peri-implant space suggested that halofuginone treatment may be an effective method for minimizing fibrous capsule formation around implants.

Original languageEnglish
Title of host publicationTransactions - 7th World Biomaterials Congress
Pages294
Number of pages1
StatePublished - 2004
Externally publishedYes
EventTransactions - 7th World Biomaterials Congress - Sydney, Australia
Duration: 17 May 200421 May 2004

Publication series

NameTransactions - 7th World Biomaterials Congress

Conference

ConferenceTransactions - 7th World Biomaterials Congress
Country/TerritoryAustralia
CitySydney
Period17/05/0421/05/04

Fingerprint

Dive into the research topics of 'Tempostatin™ (halofuginone) inhibits collagen deposition in fibrous capsules'. Together they form a unique fingerprint.

Cite this